Reuters Science News Summary

Following is a summary of current science news briefs.

Alphabet's GV leads funding in gene editing company Verve Therapeutics

GV, Alphabet Inc's venture capital arm, led a $58.5 million investment to launch Verve Therapeutics, a new biotech focused on developing therapies that edit the human genome to treat heart diseases. Gene editing therapies are seen to have huge scope in treating a range of diseases but none are currently approved. Additionally, concerns about safety and the permanent harmful effects the editing could have on humans persist.